Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ChAdOx1-HPV · 1 trial · 2 indications
Measure of adverse events, serious adverse events (SAEs), ≥Grade 3 study vaccine-related adverse events reported.
| Arm | Type | Description |
|---|---|---|
| Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^8 vp) and MVA-HPV (1 x 10\^7 pfu) |
| Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^7 pfu) |
| Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10) vp and MVA-HPV (1 x 10\^8 pfu) |
| Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^7 pfu) |
| Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10 vp) and MVA-HPV (1 x 10\^7 pfu) |
| Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^8 vp) and MVA-HPV (1 x 10\^8 pfu) |
| Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^8 pfu) |
| Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10 vp) and MVA-HPV (1 x 10\^8 pfu) |
| Group 6 Placebo Saline | PLACEBO_COMPARATOR | Sodium Chloride (0.9%) |
| Name | Type | Description |
|---|---|---|
| ChAdOx1-HPV | BIOLOGICAL | Trial vaccine |
| MVA-HPV | BIOLOGICAL | Trial vaccine |
| Placebo | BIOLOGICAL | Saline placebo vaccine |
Inclusion Criteria: 1. Females aged ≥25 and ≤55 years of age at screening. 2. Persistent hrHPV infection defined as a documented cervical infection with hrHPV type(s) in the 6 to 18 months prior to screening and confirmed at screening (participants in the main and expansion phases only). Participan...
Top 20 of 28 competitors
ChAdOx1-HPV is an investigational vaccine being studied for the treatment of HPV infection, specifically in women with low-grade cervical HPV lesions (CIN1). It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
ChAdOx1-HPV is a vaccine designed to target HPV infection. It is being evaluated in women with low-grade cervical HPV lesions (CIN1) to assess its ability to generate an immune response against the virus.
ChAdOx1-HPV is being developed by Barinthus Biotherapeutics plc, a biopharmaceutical company listed on the stock exchange under the ticker symbol BRNS.
ChAdOx1-HPV is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. One Phase 1 trial has been completed.
ChAdOx1-HPV has been studied in one completed Phase 1 clinical trial, NCT04607850, titled 'Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions.' The trial enrolled 108 women aged 25 years and older with HPV infection and CIN1 in Belgium, Estonia, and the United Kingdom.
No, ChAdOx1-HPV is a vaccine, not a monoclonal antibody. It is being developed to treat HPV infection by stimulating the immune system, rather than by directly targeting the virus with antibodies.